Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 9/20 | 0.73 |
| ▸ | CTSB | P07858 | 7/20 | 0.73 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.72 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.72 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.72 |
| ▸ | CTSK | P43235 | 4/20 | 0.67 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.64 |
| ▸ | CTSS | P25774 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2253238 | 1.00 | CTSL (0.73) | CTSLCTSBPSMB1PSMB5PSMB2 | |
| SCHEMBL23234553 | 1.00 | CTSL (0.73) | CTSLCTSBPSMB1PSMB5PSMB2 | |
| SCHEMBL14341576 | 1.00 | CTSL (0.73) | CTSLCTSBPSMB1PSMB5PSMB2 | |
| SCHEMBL8259974 | 0.99 | CTSL (0.71) | CTSLCTSBPSMB1PSMB5PSMB2 | |
| SCHEMBL2141126 | 0.99 | CTSL (0.71) | CTSLCTSBPSMB1PSMB5PSMB2 | |
| SCHEMBL7028808 | 0.96 | CTSL (0.68) | CTSLCTSBPSMB1PSMB5PSMB2 | |
| SCHEMBL7028811 | 0.96 | CTSL (0.68) | CTSLCTSBPSMB1PSMB5PSMB2 | |
| SCHEMBL3054703 | 0.93 | PSMB1 (0.78) | CTSLCTSBPSMB1PSMB5PSMB2 | |
| SCHEMBL8971981 | 0.93 | PSMB1 (0.78) | CTSLCTSBPSMB1PSMB5PSMB2 | |
| SCHEMBL7710728 | 0.93 | PSMB1 (0.78) | CTSLCTSBPSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458076-B1 | HUMAN AIRWAY STEM CELLS IN LUNG EPITHELIAL ENGINEERING | MASSACHUSETTS GEN HOSPITAL (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3970725-B1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-03-27 | — | — | US | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| US-12161647-B2 | Treating hearing loss | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2024-12-10 | — | — | US | disclosed |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-09-12 | — | — | US | disclosed |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-07-23 | — | — | US | disclosed |
| US-11963968-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-04-23 | — | — | US | disclosed |
| US-11590152-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220281941-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-09-08 | — | — | US | disclosed |
| US-11370823-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3986569-A1 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | Novartis AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3972634-A2 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3970725-A1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | Massachusetts Eye & Ear Infirmary (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20130102538-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE PRESENILIN FUNCTION AND GAMMA-SECRETASE ACTIVITY | AMICUS THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-7589066-B2 | Such as N-carbobenzyloxy-phenylalanyl-phenylalanylal; for treating cancer, inflammation, and/or autoimmune diseases; suppresses endogenous antigenic peptide generation | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589066-B2 | Such as N-carbobenzyloxy-phenylalanyl-phenylalanylal; for treating cancer, inflammation, and/or autoimmune diseases; suppresses endogenous antigenic peptide generation | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-09-15 | — | — | US | disclosed |
| WO-2006099261-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370823-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | CTSL 3830/4885CTSB 2491/4885PSMB1 658/4885 |
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | GSK3B, GSKIP, BACE1 | CTSL 2232/4885CTSB 691/4885PSMB1 109/4885 |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | CTSL 4761/4885CTSB 3999/4885PSMB1 1287/4885 |
| US-20220281941-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | HES1, NOTCH1, NOTCH2 | CTSL 3830/4885CTSB 2491/4885PSMB1 658/4885 |
| US-11590152-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | CTSL 4761/4885CTSB 3999/4885PSMB1 1287/4885 |
| US-12161647-B2 | Treating hearing loss | BACE1, BACE2, PSENEN | CTSL 58/4885CTSB 33/4885PSMB1 953/4885 |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | CTSL 3830/4885CTSB 2491/4885PSMB1 658/4885 |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | HES1, NOTCH1, NOTCH4 | CTSL 1478/4885CTSB 967/4885PSMB1 3745/4885 |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | CTSL 1478/4885CTSB 967/4885PSMB1 3745/4885 |
| US-20130102538-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE PRESENILIN FUNCTION AND GAMMA-SECRETASE ACTIVITY | PSEN1, PSEN2, APP | CTSL 575/4885CTSB 201/4885PSMB1 173/4885 |
| US-12239651-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | CTSL 4761/4885CTSB 3999/4885PSMB1 1287/4885 |
| US-11963968-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | CTSL 4761/4885CTSB 3999/4885PSMB1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.